Contact
searchSearch
HMP Global

Psoriatic Arthritis Topic Center

Featured Article

News
Managing Treatment Burden in PsA and RA: Patients' Views on Methotrexate and TNFi Use
12/15/2023
Hannah Musick
“Patients experience a wide range of burden associated with treatments used for PsA and RA,” said researchers.
“Patients experience a wide range of burden associated with treatments used for PsA and RA,” said researchers.
“Patients experience a wide...
12/15/2023
First Report Managed Care
News
Bimekizumab is Safe and Effective in Treating Patients With Psoriatic Arthritis Native to Biologic Treatment, Study Finds
11/15/2023
Lisa Kuhns, PhD, MD
At week 16, 44% of patients receiving bimekizumab met the primary endpoint of 50% improvement in the American College of Rheumatology response criteria (ACR50) compared with 10% of those receiving placebo.
At week 16, 44% of patients receiving bimekizumab met the primary endpoint of 50% improvement in the American College of Rheumatology response criteria (ACR50) compared with 10% of those receiving placebo.
At week 16, 44% of patients...
11/15/2023
First Report Managed Care
News
Early Detection Tool for Psoriatic Arthritis in Psoriasis Patients
10/24/2023
Danielle Sposato
The model demonstrates good performance, which can be adjusted based on its intended use, such as screening or targeting high-risk individuals for intervention. This tool can potentially prevent the progression from psoriasis to PsA by...
The model demonstrates good performance, which can be adjusted based on its intended use, such as screening or targeting high-risk individuals for intervention. This tool can potentially prevent the progression from psoriasis to PsA by...
The model demonstrates good...
10/24/2023
First Report Managed Care
News
Persistence, Switching in Patients With PsA Similar With Ixekizumab and Secukinumab
09/12/2023
Jolynn Tumolo
Researchers found that real-world treatment patterns and use of adjunctive pain and anti-inflammatory medications may be similar in patients with PsA initiating ixekizumab and secukinumab. 
Researchers found that real-world treatment patterns and use of adjunctive pain and anti-inflammatory medications may be similar in patients with PsA initiating ixekizumab and secukinumab. 
Researchers found that...
09/12/2023
First Report Managed Care
News
New and Previous Chronic Inflammatory Disease Diagnoses Increases Treatment Costs
08/22/2023
Jolynn Tumolo
Newly-diagnosed patients with chronic inflammatory diseases previously diagnosed with psoriasis, psoriatic arthritis, axial spondyloarthritis, or hidradenitis suppurative experienced increased treatment costs the year after diagnosis.
Newly-diagnosed patients with chronic inflammatory diseases previously diagnosed with psoriasis, psoriatic arthritis, axial spondyloarthritis, or hidradenitis suppurative experienced increased treatment costs the year after diagnosis.
Newly-diagnosed patients with...
08/22/2023
First Report Managed Care
News
Cardiometabolic, Mental Health Disorders Common in Patients With PsA
07/27/2023
Jolynn Tumolo
"Future studies are needed for a better understanding of the pathogenic mechanisms of, and the development of better protocols for the identification and treatment of patients with, comorbidities in patients with PsA," said researchers. 
"Future studies are needed for a better understanding of the pathogenic mechanisms of, and the development of better protocols for the identification and treatment of patients with, comorbidities in patients with PsA," said researchers. 
"Future studies are needed for a...
07/27/2023
First Report Managed Care
News
Sleep Problems Common Among Patients With Psoriatic Arthritis
06/16/2023
Jolynn Tumolo
A new meta-analysis reveals that the prevalence of poor sleep quality among patients with psoriatic arthritis is 72.9%, significantly higher than in healthy controls.
A new meta-analysis reveals that the prevalence of poor sleep quality among patients with psoriatic arthritis is 72.9%, significantly higher than in healthy controls.
A new meta-analysis reveals that...
06/16/2023
First Report Managed Care
News
Synovio-Enthesitis on Ultrasound May Detect Subclinical PsA
05/18/2023
Jolynn Tumolo
“Routine ultrasound evaluation could help screen [patients with psoriasis] in the subclinical psoriatic arthritis phase,” wrote the research team.
“Routine ultrasound evaluation could help screen [patients with psoriasis] in the subclinical psoriatic arthritis phase,” wrote the research team.
“Routine ultrasound evaluation...
05/18/2023
First Report Managed Care
News
JAK Inhibitor Improves Symptoms in Patients With Psoriatic Arthritis and Axial Involvement
04/21/2023
Jolynn Tumolo
In two phase 3 studies comparing upadacitinib to placebo and adalimumab, upadacitinib improved symptoms in patients with psoriatic arthritis and axial involvement.
In two phase 3 studies comparing upadacitinib to placebo and adalimumab, upadacitinib improved symptoms in patients with psoriatic arthritis and axial involvement.
In two phase 3 studies comparing...
04/21/2023
First Report Managed Care
News
IL-23 Inhibitors Outperform Placebo for Treatment of Psoriatic Arthritis, Meta-Analysis Shows
03/16/2023
Jolynn Tumolo
“IL-23 inhibitors have the potential to be a promising therapeutic option, especially for...patients who have an insufficient response to conventional synthetic disease-modifying antirheumatic drugs,” researchers wrote.
“IL-23 inhibitors have the potential to be a promising therapeutic option, especially for...patients who have an insufficient response to conventional synthetic disease-modifying antirheumatic drugs,” researchers wrote.
“IL-23 inhibitors have the...
03/16/2023
First Report Managed Care
News
IL-17A Inhibition With Treatment Improves Symptoms of Psoriatic Arthritis
10/27/2022
Edan Stanley
Utilizing Power Doppler ultrasound, researchers examined the dynamics of response of synovitis to IL-17A inhibition with secukinumab in patients with active psoriatic arthritis.
Utilizing Power Doppler ultrasound, researchers examined the dynamics of response of synovitis to IL-17A inhibition with secukinumab in patients with active psoriatic arthritis.
Utilizing Power Doppler...
10/27/2022
First Report Managed Care

Newsfeed

News
Managing Treatment Burden in PsA and RA: Patients' Views on Methotrexate and TNFi Use
12/15/2023
Hannah Musick
“Patients experience a wide range of burden associated with treatments used for PsA and RA,” said researchers.
“Patients experience a wide range of burden associated with treatments used for PsA and RA,” said researchers.
“Patients experience a wide...
12/15/2023
First Report Managed Care
News
Bimekizumab is Safe and Effective in Treating Patients With Psoriatic Arthritis Native to Biologic Treatment, Study Finds
11/15/2023
Lisa Kuhns, PhD, MD
At week 16, 44% of patients receiving bimekizumab met the primary endpoint of 50% improvement in the American College of Rheumatology response criteria (ACR50) compared with 10% of those receiving placebo.
At week 16, 44% of patients receiving bimekizumab met the primary endpoint of 50% improvement in the American College of Rheumatology response criteria (ACR50) compared with 10% of those receiving placebo.
At week 16, 44% of patients...
11/15/2023
First Report Managed Care
News
Early Detection Tool for Psoriatic Arthritis in Psoriasis Patients
10/24/2023
Danielle Sposato
The model demonstrates good performance, which can be adjusted based on its intended use, such as screening or targeting high-risk individuals for intervention. This tool can potentially prevent the progression from psoriasis to PsA by...
The model demonstrates good performance, which can be adjusted based on its intended use, such as screening or targeting high-risk individuals for intervention. This tool can potentially prevent the progression from psoriasis to PsA by...
The model demonstrates good...
10/24/2023
First Report Managed Care
News
Persistence, Switching in Patients With PsA Similar With Ixekizumab and Secukinumab
09/12/2023
Jolynn Tumolo
Researchers found that real-world treatment patterns and use of adjunctive pain and anti-inflammatory medications may be similar in patients with PsA initiating ixekizumab and secukinumab. 
Researchers found that real-world treatment patterns and use of adjunctive pain and anti-inflammatory medications may be similar in patients with PsA initiating ixekizumab and secukinumab. 
Researchers found that...
09/12/2023
First Report Managed Care
News
New and Previous Chronic Inflammatory Disease Diagnoses Increases Treatment Costs
08/22/2023
Jolynn Tumolo
Newly-diagnosed patients with chronic inflammatory diseases previously diagnosed with psoriasis, psoriatic arthritis, axial spondyloarthritis, or hidradenitis suppurative experienced increased treatment costs the year after diagnosis.
Newly-diagnosed patients with chronic inflammatory diseases previously diagnosed with psoriasis, psoriatic arthritis, axial spondyloarthritis, or hidradenitis suppurative experienced increased treatment costs the year after diagnosis.
Newly-diagnosed patients with...
08/22/2023
First Report Managed Care
News
Cardiometabolic, Mental Health Disorders Common in Patients With PsA
07/27/2023
Jolynn Tumolo
"Future studies are needed for a better understanding of the pathogenic mechanisms of, and the development of better protocols for the identification and treatment of patients with, comorbidities in patients with PsA," said researchers. 
"Future studies are needed for a better understanding of the pathogenic mechanisms of, and the development of better protocols for the identification and treatment of patients with, comorbidities in patients with PsA," said researchers. 
"Future studies are needed for a...
07/27/2023
First Report Managed Care
News
Sleep Problems Common Among Patients With Psoriatic Arthritis
06/16/2023
Jolynn Tumolo
A new meta-analysis reveals that the prevalence of poor sleep quality among patients with psoriatic arthritis is 72.9%, significantly higher than in healthy controls.
A new meta-analysis reveals that the prevalence of poor sleep quality among patients with psoriatic arthritis is 72.9%, significantly higher than in healthy controls.
A new meta-analysis reveals that...
06/16/2023
First Report Managed Care
News
Synovio-Enthesitis on Ultrasound May Detect Subclinical PsA
05/18/2023
Jolynn Tumolo
“Routine ultrasound evaluation could help screen [patients with psoriasis] in the subclinical psoriatic arthritis phase,” wrote the research team.
“Routine ultrasound evaluation could help screen [patients with psoriasis] in the subclinical psoriatic arthritis phase,” wrote the research team.
“Routine ultrasound evaluation...
05/18/2023
First Report Managed Care
News
JAK Inhibitor Improves Symptoms in Patients With Psoriatic Arthritis and Axial Involvement
04/21/2023
Jolynn Tumolo
In two phase 3 studies comparing upadacitinib to placebo and adalimumab, upadacitinib improved symptoms in patients with psoriatic arthritis and axial involvement.
In two phase 3 studies comparing upadacitinib to placebo and adalimumab, upadacitinib improved symptoms in patients with psoriatic arthritis and axial involvement.
In two phase 3 studies comparing...
04/21/2023
First Report Managed Care
News
IL-23 Inhibitors Outperform Placebo for Treatment of Psoriatic Arthritis, Meta-Analysis Shows
03/16/2023
Jolynn Tumolo
“IL-23 inhibitors have the potential to be a promising therapeutic option, especially for...patients who have an insufficient response to conventional synthetic disease-modifying antirheumatic drugs,” researchers wrote.
“IL-23 inhibitors have the potential to be a promising therapeutic option, especially for...patients who have an insufficient response to conventional synthetic disease-modifying antirheumatic drugs,” researchers wrote.
“IL-23 inhibitors have the...
03/16/2023
First Report Managed Care
News
FDA Issues Final Guidance on Biosimilar Prior Approval Supplements
09/10/2025
Grace Taylor, MS, MA
The US Food and Drug Administration (FDA) has finalized guidance clarifying 6 categories of biosimilar prior approval supplements, setting review goals that could shape timelines for new indications and payer coverage decisions.
The US Food and Drug Administration (FDA) has finalized guidance clarifying 6 categories of biosimilar prior approval supplements, setting review goals that could shape timelines for new indications and payer coverage decisions.
The US Food and Drug...
09/10/2025
First Report Managed Care
News
High Health Care Burden Among People with Hemophilia A Experiencing Bleeding or Joint Complications
09/10/2025
Juliet Gallagher
New real-world evidence shows that people with hemophilia A who experience bleeding or joint complications face significantly higher health care utilization and comorbidity burden.
New real-world evidence shows that people with hemophilia A who experience bleeding or joint complications face significantly higher health care utilization and comorbidity burden.
New real-world evidence shows...
09/10/2025
First Report Managed Care
News
Confronting the HIV Epidemic: Addressing Gaps in Access, Adherence, and Equity
09/02/2025
Juliet Gallagher
At a recent AMCP conference, health care leaders Maria Lopes, MD, and Steve Cohen, MD, highlighted the persistent and unique challenges of HIV management in the US, emphasizing that despite medical advancements, HIV remains classified as an...
At a recent AMCP conference, health care leaders Maria Lopes, MD, and Steve Cohen, MD, highlighted the persistent and unique challenges of HIV management in the US, emphasizing that despite medical advancements, HIV remains classified as an...
At a recent AMCP conference,...
09/02/2025
First Report Managed Care
News
Industry Payments and Their Role in MS Drug Selection Among High-Volume Prescribers
08/28/2025
Juliet Gallagher
A recent observational study explored the prevalence of industry payments to neurologists who prescribe multiple sclerosis (MS) disease-modifying therapies (DMTs), uncovering significant associations between such payments and prescribing...
A recent observational study explored the prevalence of industry payments to neurologists who prescribe multiple sclerosis (MS) disease-modifying therapies (DMTs), uncovering significant associations between such payments and prescribing...
A recent observational study...
08/28/2025
First Report Managed Care
News
Medicare Advantage Plans See Double-Digit Satisfaction Drop as Medical Costs Soar
08/22/2025
Juliet Gallagher
Member satisfaction with Medicare Advantage (MA) plans has seen a significant decline, according to J.D. Power’s 2025 report, reflecting a broader set of financial and policy pressures now facing the MA landscape.
Member satisfaction with Medicare Advantage (MA) plans has seen a significant decline, according to J.D. Power’s 2025 report, reflecting a broader set of financial and policy pressures now facing the MA landscape.
Member satisfaction with...
08/22/2025
First Report Managed Care
News
Expanding Assertive Community Treatment to Transform Care for Complex Patients
08/20/2025
Lisa Kuhns, PhD, MD
A new study shows that health systems can rely on assertive community treatment (ACT), which has strong evidence supporting its effectiveness for treating the most complex, least engaged patients.
A new study shows that health systems can rely on assertive community treatment (ACT), which has strong evidence supporting its effectiveness for treating the most complex, least engaged patients.
A new study shows that health...
08/20/2025
First Report Managed Care
News
AAM White Paper Spotlights Legislative Path to Breaking Biosimilar Patent Barriers
08/18/2025
Grace Taylor, MS, MA
A recent white paper from the Association for Accessible Medicines exposes how brand-name drug patent tactics block biosimilar access and urges Congress to act on 3 key reforms to lower drug costs.
A recent white paper from the Association for Accessible Medicines exposes how brand-name drug patent tactics block biosimilar access and urges Congress to act on 3 key reforms to lower drug costs.
A recent white paper from the...
08/18/2025
First Report Managed Care
News
FDA Expands Approval of Alhemo for Hemophilia A and B Without Inhibitors
08/14/2025
Juliet Gallagher
Novo Nordisk has announced the US Food and Drug Administration (FDA) approval of Alhemo (concizumab-mtci) for use as a once-daily subcutaneous prophylactic treatment in people 12 years and older with hemophilia A or B (HA/HB) without...
Novo Nordisk has announced the US Food and Drug Administration (FDA) approval of Alhemo (concizumab-mtci) for use as a once-daily subcutaneous prophylactic treatment in people 12 years and older with hemophilia A or B (HA/HB) without...
Novo Nordisk has announced the...
08/14/2025
First Report Managed Care
News
High-Efficacy Multiple Sclerosis Therapies Linked to Fewer Emergency Department Visits and Lower Risk
08/13/2025
Lisa Kuhns, PhD, MD
High-efficacy disease-modifying therapies (DMTs) for multiple sclerosis (MS) are linked to a reduced likelihood of emergency department (ED) visits, according to a study published in Neurology.
High-efficacy disease-modifying therapies (DMTs) for multiple sclerosis (MS) are linked to a reduced likelihood of emergency department (ED) visits, according to a study published in Neurology.
High-efficacy disease-modifying...
08/13/2025
First Report Managed Care
News
Roctavian Demonstrates Sustained Efficacy and Safety in Patients With Hemophilia A
08/04/2025
Grace Taylor, MS, MA
Five-year data from BioMarin’s phase 3 trial reveals Roctavian’s long-term efficacy, safety, and quality-of-life benefits for adults with severe hemophilia A.
Five-year data from BioMarin’s phase 3 trial reveals Roctavian’s long-term efficacy, safety, and quality-of-life benefits for adults with severe hemophilia A.
Five-year data from BioMarin’s...
08/04/2025
First Report Managed Care

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use